Tag: TOTUM070
Valbiotis presents the positive complementary results of the HEART clinical study on TOTUM•070 against hypercholesterolemia – 03/10/2022 at 07:35
• TOTUM•070 obtains excellent results in volunteers who had a blood level of LDL cholesterol greater than 130 mg/dl at randomization, its commercially targeted population and main subpopulation of the…
Valbiotis announces the broad success of the HEART Phase II clinical study: TOTUM•070, a patented plant-based active substance, demonstrates its efficacy against hypercholesterolemia, a cardiovascular risk factor – 06/13/2022 at 6:30 p.m.
• This Phase II clinical study with TOTUM•070, randomized and controlled against placebo, achieves its objective of reducing LDL cholesterol (primary endpoint) and confirms the very good tolerance of this…